Oncology CROs: Navigating CRO Selection for Clinical Trial Success
Oncology remains the largest therapeutic segment in clinical research, with over 30% of all active clinical trials globally focused on cancer indications. The contract research organization landscape for oncology has evolved from generalist service providers into a sophisticated ecosystem of specialized partners offering deep therapeutic expertise, biomarker-driven trial design, and global regulatory capabilities.
Market Landscape
The global oncology clinical trials market was valued at approximately $13 billion in 2022 and continues to grow at a CAGR of 5.2%. This growth is fueled by the rise of precision medicine, immuno-oncology, and cell and gene therapies that demand increasingly complex trial designs—basket trials, umbrella trials, and adaptive platform protocols.
The CRO industry itself is a $80+ billion market, with oncology representing its single largest therapeutic vertical. Over 1,100 CROs operate globally, though the number with dedicated oncology capabilities and meaningful trial track records is considerably smaller.
What Differentiates an Oncology CRO
- Therapeutic Depth vs. Breadth
- Full-service CROs like IQVIA and ICON offer scale across all therapeutic areas, while specialists like Precision for Medicine and Theradex bring deep oncology-first expertise. The right choice depends on your program’s complexity and stage.
- Biomarker and Translational Capabilities
- Modern oncology trials are increasingly biomarker-driven. CROs with integrated central labs, next-generation sequencing (NGS), and companion diagnostic development capabilities—such as Precision for Medicine with its library of 13,000+ characterized biospecimens—offer a meaningful advantage.
- Regulatory Track Record
- PPD (Thermo Fisher) has supported 34 oncology drug approvals in the US and 25 in the EU over the past five years. This kind of regulatory pedigree directly impacts your probability of approval.
Regional Considerations
Site selection and patient recruitment strategy vary significantly by region. Asia-Pacific has emerged as a critical geography, with 50% of new clinical trials now including APAC sites. Novotech, with 3,000+ staff and 5,000+ partner sites across the region, has conducted nearly 300 oncology studies and leads in APAC trial execution.
For early-phase work, Australia and New Zealand offer regulatory advantages including the Clinical Trial Notification (CTN) scheme, which enables faster trial initiation. Late-phase studies increasingly leverage large patient populations in China, India, and South Korea.
CRO Selection Criteria for Oncology Trials
| Criterion | Why It Matters |
|---|---|
| Indication-specific experience | CROs with prior trials in your exact tumor type understand site selection, endpoint nuances, and enrollment challenges |
| Phase expertise | Phase I dose-escalation designs require different capabilities than Phase III registration trials |
| Central lab integration | Reduces turnaround time for biomarker assays and companion diagnostics |
| Regulatory submission support | Experience with FDA, EMA, and PMDA oncology divisions accelerates approval timelines |
| Patient recruitment network | Access to oncology centers of excellence and community oncology sites drives enrollment speed |